Quince Therapeutics, Inc. (QNCX)
NASDAQ: QNCX · Real-Time Price · USD
1.230
-0.060 (-4.65%)
At close: Apr 28, 2026, 4:00 PM EDT
1.220
-0.010 (-0.80%)
After-hours: Apr 28, 2026, 7:58 PM EDT
Quince Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Selling, General & Admin | 15.05 | 17.58 | 15.4 | 24.91 | 29.52 | |
| Research & Development | 35.38 | 18.59 | 9.25 | 25.18 | 60.8 | |
| Operating Expenses | 50.43 | 36.17 | 24.64 | 50.09 | 90.32 | |
| Operating Income | -50.43 | -36.17 | -24.64 | -50.09 | -90.32 | |
| Interest Expense | -0.91 | - | - | - | - | |
| Interest & Investment Income | 1.24 | 2.93 | 3.48 | 1.07 | 0.62 | |
| Currency Exchange Gain (Loss) | 0.49 | -0.68 | 0 | -0.77 | -0.25 | |
| Other Non Operating Income (Expenses) | -21.47 | - | - | - | - | |
| EBT Excluding Unusual Items | -71.08 | -33.92 | -21.16 | -49.79 | -89.95 | |
| Merger & Restructuring Charges | - | - | -2.5 | -1.1 | - | |
| Impairment of Goodwill | - | -17.13 | - | -0.83 | - | |
| Gain (Loss) on Sale of Assets | - | - | -0.04 | -0.09 | - | |
| Asset Writedown | - | - | -5.97 | -0.14 | - | |
| Other Unusual Items | -9.68 | -5.69 | -1.92 | - | - | |
| Pretax Income | -80.77 | -56.74 | -31.58 | -51.94 | -89.95 | |
| Income Tax Expense | 3.21 | 0.09 | -0.2 | -0.28 | - | |
| Net Income | -83.98 | -56.83 | -31.39 | -51.66 | -89.95 | |
| Net Income to Common | -83.98 | -56.83 | -31.39 | -51.66 | -89.95 | |
| Shares Outstanding (Basic) | 5 | 4 | 4 | 3 | 3 | |
| Shares Outstanding (Diluted) | 5 | 4 | 4 | 3 | 3 | |
| Shares Change (YoY) | 15.80% | 16.18% | 11.17% | 12.71% | 1.86% | |
| EPS (Basic) | -16.76 | -13.14 | -8.43 | -15.42 | -30.27 | |
| EPS (Diluted) | -16.76 | -13.14 | -8.43 | -15.42 | -30.27 | |
| Free Cash Flow | -41.78 | -32.16 | -18.45 | -44.17 | -63.11 | |
| Free Cash Flow Per Share | -8.34 | -7.43 | -4.96 | -13.19 | -21.24 | |
| EBITDA | -50.29 | -35.98 | -24.32 | -49.89 | -89.97 | |
| D&A For EBITDA | 0.14 | 0.19 | 0.32 | 0.2 | 0.34 | |
| EBIT | -50.43 | -36.17 | -24.64 | -50.09 | -90.32 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.